FDA 483 OBSERVATION · #786 OF 1,000 MOST-CITED
Adequate space lacking to prevent mix-ups and contamination
FDA cited this observation 20 times across 20 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.
How FDA worded it — real examples
The building lacks adequate space for the orderly placement of equipment and materials to prevent mix-ups between different components, drug product containers, closures, labeling, in-process materials and drug products and to prevent contamination.
The building lacks adequate space for the orderly placement of equipment and materials to prevent mix-ups between different components and drug products and to prevent contamination.
The building lacks adequate space for the orderly placement of equipment and materials to prevent mix-ups between in-process materials and drug products and to prevent contamination.
The building lacks adequate space for the orderly placement of equipment and materials to prevent mix-ups between different components and drug products and to prevent contamination.
The building lacks adequate space for the orderly placement of equipment and materials to prevent mix-ups between drug product containers, closures and drug products and to prevent contamination.
The building lacks adequate space for the orderly placement of equipment and materials to prevent mix-ups between drug product containers, in-process materials and drug products and to prevent contamination.
Related SPEQ references
Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.
Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.
Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.